Search results
309 Results for 'Drug Development'
- Technologies (18)
- Collaborations (1)
- Team (0)
- News (226)
- Events (0)
- Multimedia (64)
- Publications (0)
- Jobs (0)
Technologies 18
-
SomaCode: Getting cell therapies where they need to go
The Problem Cell therapies, which involve using whole, living cells to treat disease, have been heralded as a next-generation treatment paradigm for a wide variety of illnesses and conditions. However, diseases are very complex, and therapeutic cells need to be able to demonstrate equally complex behaviors in order to effectively treat them. Among the largest... -
CircaVent: A Drug Discovery Platform for Mental Health Conditions
CircaVent is a novel drug discovery platform that combines predictive algorithms, high-throughput preclinical models, and human organoids to identify and test drugs that could treat mental health conditions like bipolar disorder. -
Rapid Metabolite-Sensing System for Blood Lactate
In emergency medicine, blood lactate levels are a reliable real-time indicator of the severity and mortality risk of conditions that occur as a result of poor blood circulation and oxygen supply to organs and tissues (hypoperfusion), such as in patients with sepsis, cardiac arrest, stroke, major trauma, cystic fibrosis and other conditions. Lactate levels also... -
DNA Nanotechnology Tools: From Design to Applications
A suite of diverse, multifunctional DNA nanotechnological tools with unique capabilities and potential for a broad range of clinical and biomedical research areas. Our DNA nanotechnology devices were engineered to overcome specific bottlenecks in the development of new therapies and diagnostics, and to help further our understanding of molecular structures. -
eRNA: Controlled Enzymatic RNA Oligonucleotide Synthesis
Synthetic RNA oligonucleotides designed as specific successions of the four nucleobases A, U, G, and C that mimic naturally occurring RNA species are the key components of diverse RNA-based therapies. These include RNA therapeutics that can partially or completely turn off the expression of disease-causing genes (antisense and interfering RNAs), help replace or supplement dysfunctional... -
CogniXense: Target-Agnostic Drug Repurposing in Record Time
The problem There are more than 7,000 known rare genetic diseases that collectively afflict more patients in the United States than diabetes, but only 5% of these diseases have any effective treatment. A major driver of this lack of therapies is that about 75% of rare genetic diseases cause cognitive and behavioral impairment, which are...
Collaborations 1
Brain Targeting ProgramNews 226
Multimedia 64
-
Video/AnimationFrontier Science #10: Bioelectrics w/ Michael LevinMichael Levin, a Wyss Associate Faculty member and a Distinguished Professor in the Biology department at Tufts, holds the Vannevar Bush endowed Chair and serves as director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. Recent honors include the Scientist of Vision award and the Distinguished Scholar... -
Video/AnimationeToehold: an RNA-detecting control element for use in RNA therapeutics, diagnostics and cell therapiesThis animation shows an example of an eToehold that detects and signals the presence of a specific viral RNA in a human cell. After the virus has injected its RNA into a host cell, the RNA acts as a “trigger RNA” by binding to a complementary sequence within the eToehold specifically engineered for its detection.... -
Video/AnimationWyss Institute Brain Targeting ProgramThis animation explains how Wyss Institute researchers and their industry partners aim to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at...